Lycia Therapeutics stock surges in IPO debut after pricing about $317.5M offering

What happened: Lycia Therapeutics, a drug developer, surged in its IPO debut after pricing an offering of 17.64 million shares at $18 each. Key numbers: 17.64 million shares at $18 each, about $317.5M offering, expected close on Oct. 26. Why it matters: The stock's surge in its debut followed the pricing of the offering, which is expected to close on Oct. 26.

Lycia Therapeutics, a drug developer, surged in its IPO debut after pricing an offering of 17.64 million shares at $18 each.

The stock's surge in its debut followed the pricing of the offering, which is expected to close on Oct. 26.